Showing 5741-5750 of 8592 results for "".
- Ivarmacitinib Demonstrates Efficacy in Phase 3 Trial for Atopic Dermatitishttps://practicaldermatology.com/news/ivarmacitinib-demonstrates-efficacy-in-phase-3-trial-for-atopic-dermatitis/2474409/A new Phase 3 randomized clinical trial shows that ivarmacitinib, an oral JAK1 inhibitor, significantly improves clinical signs of moderate to severe atopic dermatitis (AD) in both adolescents and adults with a favorable safety profile.
- From ASLMS: Advances in Infantile Hemangioma Diagnosis and Carehttps://practicaldermatology.com/news/from-aslms-advances-in-infantile-hemangioma-diagnosis-and-care/2474328/New guidelines from the International Society for the Study of Vascular Anomalies (ISSVA) offer more precise classification and improved multidisciplinary pathways for patient care. Kristen Kelly, MD, Professor of Dermatology and Surgery a
- Study Shows Prognostic Value of 40-GEP in Advanced cSCChttps://practicaldermatology.com/news/study-shows-prognostic-value-of-40-gep-in-advanced-cscc/2474383/A new multi-institutional study indicates that a 40-gene expression profile (40-GEP) test with traditional staging enhances risk stratification for cutaneous squamous cell carcinoma (cSCC), even among patients already categorized as high- or very-high-risk using Na
- FDA Gives Nod to First Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fda-gives-nod-to-first-cell-based-gene-therapy-for-recessive-dystrophic-epidermolysis-bullosa/2474382/The U.S. Food and Drug Administration (FDA) has approved ZEVASKYN (prademagene zamikeracel, pz-cel), making it the first cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The approval addresses a major unmet clinical nee
- From ASLMS 2025: Dr. Joel Cohen Highlights New Fractional Laser Techniques, Including Laser-enabled Tissue Coringhttps://practicaldermatology.com/news/from-aslms-dr-joel-cohen-highlights-new-fractional-laser-techniques-for-scars-at-aslms/2474327/During a fractional laser section of the recent program of the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, board-certified dermatologist, Mohs surgeon, and laser expert Joel L. Cohen, MD, FAAD, FACMS, presented clinical insights into fractional laser us
- From ASLMS 2025: New Laser Platforms Expand Options for Vascular Rosaceahttps://practicaldermatology.com/news/new-laser-platforms-expand-options-for-vascular-rosacea/2474325/Advanced vascular lasers are transforming the treatment of rosacea by targeting its root cause (chronic vascular dilation) rather than just managing inflammation. At the 2025 American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando, Eric Bernstein, MD, Director of
- Candela Launches Dual-Wavelength Vbeam Pro for Vascular and Dermatologic Conditionshttps://practicaldermatology.com/news/candela-launches-dual-wavelength-vbeam-pro-for-vascular-and-dermatologic-conditions/2474321/Candela has introduced its latest pulsed dye laser platform, the Vbeam Pro, at the 2025 Annual Meeting of the American Society for Laser Medicine and Surgery (ASLMS) in Orlando, Florida.
- EARLY: Guselkumab Use Supported in PsO Patients With HBV, Cancer, or Heart Diseasehttps://practicaldermatology.com/news/early-guselkumab-use-supported-in-pso-patients-with-hbv-cancer-or-heart-disease/2474211/Guselkumab, an IL-23 inhibitor approved for moderate-to-severe psoriasis, showed long-term safety in patients with complex comorbidities—including chronic infections, prior malignancies, and cardiovascular disease—according to findings from the EARLY Study.
- Tattoo Removal Trends Revealed in Global Analysis of Over 200,000 Individualshttps://practicaldermatology.com/news/tattoo-removal-trends-revealed-in-global-analysis-of-over-200000-individuals/2474320/Laser tattoo removal is increasingly sought by individuals across the globe, according to new research presented at the American Society for Laser Medicine and Surgery (ASLMS) Annual Meeting in Orlando. The data were presente
- AVAVA Receives FDA Clearance for Acne Scar Treatment on All Skin Types Using Focal Point Technologyhttps://practicaldermatology.com/news/avava-receives-fda-clearance-for-acne-scar-treatment-on-all-skin-types-using-focal-point-technology/2474319/The U.S. Food and Drug Administration (FDA) has cleared AVAVA’s Focal Point Technology™ for the treatment of acne scars, marking a significant milestone in energy-based skin therapy. The technology, developed by Boston-based AVAVA, is now indicated for acne scarring in all Fitzpatrick sk